Olaparib Reduced Pain and Yielded Better-Preserved HRQOL in Metastatic CRPC
May 19th 2022Results from a phase 3 trial indicated that olaparib yielded better-preserved health-related quality of life and reduced pain burden vs the control for patients with homologous recombination repair gene–altered metastatic castration-resistant prostate cancer who progressed following a prior next-generation hormonal drug.